The present invention relates to apparatus and methods useful in connection with performing electrical cardioversion/defibrillation and optional pacing of the heart.
Defibrillation/cardioversion is a technique employed to counter arrhythmic heart conditions including some tachycardias in the atria and/or ventricles. Typically, electrodes are employed to stimulate the heart with electrical impulses or shocks, of a magnitude substantially greater than pulses used in cardiac pacing.
Defibrillation/cardioversion systems include body implantable electrodes that are connected to a hermetically sealed container housing the electronics, battery supply and capacitors. The entire system is referred to as implantable cardioverter/defibrillators (ICDs). The electrodes used in ICDs can be in the form of patches applied directly to epicardial tissue, or, more commonly, are on the distal regions of small cylindrical insulated catheters that typically enter the subclavian venous system, pass through the superior vena cava and, into one or more endocardial areas of the heart. Such electrode systems are called intravascular or transvenous electrodes. U.S. Pat. Nos. 4,603,705; 4,693,253; 4,944,300; and 5,105,810, the disclosures of which are all incorporated herein by reference, disclose intravascular or transvenous electrodes, employed either alone, in combination with other intravascular or transvenous electrodes, or in combination with an epicardial patch or subcutaneous electrodes. Compliant epicardial defibrillator electrodes are disclosed in U.S. Pat. Nos. 4,567,900 and 5,618,287, the disclosures of which are incorporated herein by reference. A sensing epicardial electrode configuration is disclosed in U.S. Pat. No. 5,476,503, the disclosure of which is incorporated herein by reference.
In addition to epicardial and transvenous electrodes, subcutaneous electrode systems have also been developed. For example, U.S. Pat. Nos. 5,342,407 and 5,603,732, the disclosures of which are incorporated herein by reference, teach the use of a pulse monitor/generator surgically implanted into the abdomen and subcutaneous electrodes implanted in the thorax. This system is far more complicated to use than current ICD systems using transvenous lead systems together with an active can electrode and therefore it has no practical use. It has in fact never been used because of the surgical difficulty of applying such a device (3 incisions), the impractical abdominal location of the generator and the electrically poor sensing and defibrillation aspects of such a system.
Recent efforts to improve the efficiency of ICDs have led manufacturers to produce ICDs which are small enough to be implanted in the pectoral region. In addition, advances in circuit design have enabled the housing of the ICD to form a subcutaneous electrode. Some examples of ICDs in which the housing of the ICD serves as an optional additional electrode are described in U.S. Pat. Nos. 5,133,353; 5,261,400; 5,620,477; and 5,658,321, the disclosures of which are incorporated herein by reference.
ICDs are now an established therapy for the management of life threatening cardiac rhythm disorders, primarily ventricular fibrillation (V-Fib). ICDs are very effective at treating V-Fib, but are therapies that still require significant surgery.
As ICD therapy becomes more prophylactic in nature and used in progressively less ill individuals, especially children at risk of cardiac arrest, the requirement of ICD therapy to use intravenous catheters and transvenous leads is an impediment to very long term management as most individuals will begin to develop complications related to lead system malfunction sometime in the 5-10 year time frame, often earlier. In addition, chronic transvenous lead systems, their reimplantation and removals, can damage major cardiovascular venous systems and the tricuspid valve, as well as result in life threatening perforations of the great vessels and heart. Consequently, use of transvenous lead systems, despite their many advantages, are not without their chronic patient management limitations in those with life expectancies of >5 years. The problem of lead complications is even greater in children where body growth can substantially alter transvenous lead function and lead to additional cardiovascular problems and revisions. Moreover, transvenous ICD systems also increase cost and require specialized interventional rooms and equipment as well as special skill for insertion. These systems are typically implanted by cardiac electrophysiologists who have had a great deal of extra training.
In addition to the background related to ICD therapy, the present invention requires a brief understanding of a related therapy, the automatic external defibrillator (AED) AEDs employ the use of cutaneous patch electrodes, rather than implantable lead systems, to effect defibrillation under the direction of a bystander user who treats the patient suffering from V-Fib with a portable device containing the necessary electronics and power supply that allows defibrillation. AEDs can be nearly as effective as an ICD for defibrillation if applied to the victim of ventricular fibrillation promptly, i.e., within 2 to 3 minutes of the onset of the ventricular fibrillation.
AED therapy has great appeal as a tool for diminishing the risk of death in public venues such as in air flight. However, an AED must be used by another individual, not the person suffering from the potential fatal rhythm. It is more of a public health tool than a patient-specific tool like an ICD. Because >75% of cardiac arrests occur in the home, and over half occur in the bedroom, patients at risk of cardiac arrest are often alone or asleep and can not be helped in time with an AED. Moreover, its success depends to a reasonable degree on an acceptable level of skill and calm by the bystander user.
What is needed therefore, especially for children and for prophylactic long term use for those at risk of cardiac arrest, is a combination of the two forms of therapy which would provide prompt and near-certain defibrillation, like an ICD, but without the long-term adverse sequelae of a transvenous lead system while simultaneously using most of the simpler and lower cost technology of an AED. What is also needed is a cardioverter/defibrillator that is of simple design and can be comfortably implanted in a patient for many years.
Moreover, it has appeared advantageous to the inventor to provide the capability in such improved circuitry to provide a signal suitable for pacing when the circuitry is not operating in a defibrillation mode.
Accordingly, the invention relates in various aspects to methods and apparatus for selectively converting a defibrillator circuit or circuit for delivering a defibrillating pulse to a patient into circuitry suitable for providing a constant current, useful, e.g., in pacing applications.
For a better understanding of the invention, reference is now made to the drawings where like numerals represent similar objects throughout the figures and wherein:
To create a biphasic waveform such as that shown in
As in
In the circuit of
In an illustrative application of the circuitry of
V.sub.R1=V.sub.DRIVE-V.sub.T (1)
where V.sub.T is the fixed (constant) threshold voltage of the low side transistor Q.sub.1. Thus, if V.sub.DRIVE is 15 volts, and V.sub.T is in the range of 2-6 volts, V.sub.R1 is in the range of 13 to 9 volts. Accordingly, a constant voltage is applied across the resistor R.sub.1, resulting in a constant current I.sub.RI through the resistor R.sub.1, and hence through the patient R.sub.PATIENT.
As those skilled in the art may appreciate, the threshold voltage V.sub.T of the transistor Q.sub.1 may vary from device to device. Hence, it is typically necessary to calibrate the circuit in production. In calibrating a circuit like that of
In order to avoid calibration, the voltage source may be constructed using a feedback circuit employing an operational amplifier as shown in
During constant current source operation of the circuit of
V.sub.HV(min.)=V.sub.PATIENT+V.sub.COMP (2)
The higher V.sub.HV is above V.sub.HV (min.), the closer the current source will approach an ideal current source. Another consideration in setting V.sub.HV is power consumption.
The amount of current I.sub.R1 can be varied by varying the voltage V.sub.DRIVE or by switching in different resistors, e.g., in series with or for R.sub.1. From an implementation point of view, it is less attractive to switch in a resistor because such switching requires adding transistors or other switching devices. It is more efficient to simply vary the voltage V.sub.DRIVE. Suitable logic circuitry may be provided to select the value of V.sub.DRIVE. A DAC (digital to analog converter) is one example of such logic circuitry. As those skilled in the art will appreciate, a DAC is a circuit that generates different voltages in response to corresponding digital codes provided to it. Such a DAC could be used to drive either an input of the op-amp A (as illustrated in
Another illustrative circuit for implementing a current source is illustrated in
The circuit of
i=VHVR3+R PATIENT (3)##EQU00001##
While creation of a current source according to
In contrast, the circuits of
Thus, only a low voltage switch need be used in the circuits of
Provision of a constant current has the advantage of maintaining a constant current density across the heart, irrespective of the electrode interface impedance.
While the present invention has been described above in terms of specific embodiments, it is to be understood that the invention is not limited to the disclosed embodiments. On the contrary, the following claims are intended to cover various modifications and equivalent methods and structures included within the spirit and scope of the invention.
This application is a continuation of U.S. patent application Ser. No. 12/426,779, filed Apr. 20, 2009 and titled DEFIBRILLATION PACING CIRCUITRY, now U.S Patent No. 9,283,398, which is a continuation of U.S. patent application Ser. No. 11/146,607, filed Jun. 7, 2005, now U.S. Pat. No. 7,522,957 and titled DEFIBRILLATION PACING CIRCUITRY, which is a continuation of U.S. patent application Ser. No. 10/011,955, filed Nov. 5, 2001, now U.S. Pat. No. 6,952,608 and titled DEFIBRILLATION PACING CIRCUITRY, the entire disclosures of which are incorporated herein by reference. The invention of the present application may find application in systems such as is disclosed in U.S. Pat. No. 6,721,597, titled SUBCUTANEOUS ONLY IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR AND OPTIONAL PACER, and U.S. Pat. No. 6,647,292, titled UNITARY SUBCUTANEOUS ONLY IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR AND OPTIONAL PACER, and the disclosures of both applications are hereby incorporated by reference. In addition, the foregoing applications are related to: [0004] U.S. patent application Ser. No. 09/940,283, filed Aug. 27, 2001, now U.S. Pat. No. 7,065,407 and titled DUCKBILL-SHAPED IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR CANISTER AND METHOD OF USE; [0005] U.S. patent application Ser. No. 09/940,371, filed Aug. 27, 2001, now U.S. Pat. No. 7,039,465 and titled CERAMICS AND/OR OTHER MATERIAL INSULATED SHELL FOR ACTIVE AND NON-ACTIVE S-ICD CAN; [0006] U.S. patent application Ser. No. 09/940,468, filed Aug. 27, 2001, published as US 2002-0035379 A1 and titled SUBCUTANEOUS ELECTRODE FOR TRANSTHORACIC CONDUCTION WITH IMPROVED INSTALLATION CHARACTERISTICS; [0007] U.S. patent application Ser. No. 09/941,814, filed Aug. 27, 2001, published as US 2002-0035381 A1 and titled SUBCUTANEOUS ELECTRODE WITH IMPROVED CONTACT SHAPE FOR TRANSTHORACIC CONDUCTION; [0008] U.S. patent application Ser. No. 09/940,356, filed Aug. 27, 2001, published as US 2002-0035378 A1 and titled SUBCUTANEOUS ELECTRODE FOR TRANSTHORACIC CONDUCTION WITH HIGHLY MANEUVERABLE INSERTION TOOL; [0009] U.S. patent application Ser. No. 09/940,340, filed Aug. 27, 2001, now U.S. Pat. No. 6,937,907 and titled SUBCUTANEOUS ELECTRODE FOR TRANSTHORACIC CONDUCTION WITH LOW-PROFILE INSTALLATION APPENDAGE AND METHOD OF DOING SAME; [0010] U.S. patent application Ser. No. 09/940,287, filed Aug. 27, 2001, published as US 2002-0035377 A1 and titled SUBCUTANEOUS ELECTRODE FOR TRANSTHORACIC CONDUCTION WITH INSERTION TOOL; [0011] U.S. patent application Ser. No. 09/940,377, filed Aug. 27, 2001, now U.S. Pat. No. 6,866,044 and titled METHOD OF INSERTION AND IMPLANTATION OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR CANISTERS; [0012] U.S. patent application Ser. No. 09/940,599, filed Aug. 27, 2001, now U.S. Pat. No. 6,950,705 and titled CANISTER DESIGNS FOR IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; [0013] U.S. patent application Ser. No. 09/940,373, filed Aug. 27, 2001, now U.S. Pat. No. 6,788,974 and titled RADIAN CURVE SHAPED IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR CANISTER; [0014] U.S. patent application Ser. No. 09/940,273, filed Aug. 27, 2001, now U.S. Pat. No. 7,069,080 and titled CARDIOVERTER-DEFIBRILLATOR HAVING A FOCUSED SHOCKING AREA AND ORIENTATION THEREOF; [0015] U.S. patent application Ser. No. 09/940,378, filed Aug. 27, 2001, now U.S. Pat. No. 7,146,212 and titled BIPHASIC WAVEFORM FOR ANTI-BRADYCARDIA PACING FOR A SUBCUTANEOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; and [0016] U.S. patent application Ser. No. 09/940,266, filed Aug. 27, 2001, now U.S. Pat. No. 6,856,835 and titled BIPHASIC WAVEFORM FOR ANTI-TACHYCARDIA PACING FOR A SUBCUTANEOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR, the entire disclosures of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3653387 | Ceier | Apr 1972 | A |
3710374 | Kelly | Jan 1973 | A |
4191942 | Long | Mar 1980 | A |
4223678 | Langer et al. | Sep 1980 | A |
4402322 | Duggan | Sep 1983 | A |
4407288 | Langer et al. | Oct 1983 | A |
4567900 | Moore | Feb 1986 | A |
4602637 | Elmqvist et al. | Jul 1986 | A |
4603705 | Speicher et al. | Aug 1986 | A |
4693253 | Adams | Sep 1987 | A |
4800883 | Winstrom | Jan 1989 | A |
4830005 | Woskow | May 1989 | A |
4944300 | Saksena | Jul 1990 | A |
5105810 | Collins et al. | Apr 1992 | A |
5109842 | Adinolfi | May 1992 | A |
5129392 | Bardy et al. | Jul 1992 | A |
5133353 | Hauser | Jul 1992 | A |
5144946 | Weinberg et al. | Sep 1992 | A |
5184616 | Weiss | Feb 1993 | A |
5261400 | Bardy | Nov 1993 | A |
5331966 | Bennett et al. | Jul 1994 | A |
5342407 | Dahl et al. | Aug 1994 | A |
5376103 | Anderson et al. | Dec 1994 | A |
5376104 | Sakai et al. | Dec 1994 | A |
5411547 | Causey, III | May 1995 | A |
5413591 | Knoll | May 1995 | A |
5476503 | Yang | Dec 1995 | A |
5507781 | Kroll et al. | Apr 1996 | A |
5531765 | Pless | Jul 1996 | A |
5601607 | Adams | Feb 1997 | A |
5603732 | Dahl et al. | Feb 1997 | A |
5618287 | Fogarty et al. | Apr 1997 | A |
5620477 | Pless et al. | Apr 1997 | A |
5645572 | Kroll et al. | Jul 1997 | A |
5658317 | Haefner et al. | Aug 1997 | A |
5658321 | Fayram et al. | Aug 1997 | A |
5674260 | Weinberg | Oct 1997 | A |
5690683 | Haefner et al. | Nov 1997 | A |
5697953 | Kroll et al. | Dec 1997 | A |
5713926 | Hauser et al. | Feb 1998 | A |
5718242 | McClure et al. | Feb 1998 | A |
5766226 | Pedersen | Jun 1998 | A |
5836976 | Min et al. | Nov 1998 | A |
5919211 | Adams | Jul 1999 | A |
5935154 | Westlund | Aug 1999 | A |
5941904 | Johnston et al. | Aug 1999 | A |
6014586 | Weinberg et al. | Jan 2000 | A |
6026325 | Weinberg et al. | Feb 2000 | A |
6058328 | Levine et al. | May 2000 | A |
6096063 | Lopin et al. | Aug 2000 | A |
6104953 | Leyde | Aug 2000 | A |
6128531 | Campbell-Smith | Oct 2000 | A |
6144866 | Miesel et al. | Nov 2000 | A |
6169921 | KenKnight et al. | Jan 2001 | B1 |
6185450 | Seguine et al. | Feb 2001 | B1 |
6208895 | Sullivan | Mar 2001 | B1 |
6241751 | Morgan et al. | Jun 2001 | B1 |
6411844 | Kroll et al. | Jun 2002 | B1 |
6647292 | Bardy et al. | Nov 2003 | B1 |
6721597 | Bardy et al. | Apr 2004 | B1 |
6778860 | Ostroff et al. | Aug 2004 | B2 |
6788974 | Bardy et al. | Sep 2004 | B2 |
6856835 | Bardy et al. | Feb 2005 | B2 |
6866044 | Bardy et al. | Mar 2005 | B2 |
6937907 | Bardy et al. | Aug 2005 | B2 |
6950705 | Bardy et al. | Sep 2005 | B2 |
6952608 | Ostroff | Oct 2005 | B2 |
6954670 | Ostroff | Oct 2005 | B2 |
7039465 | Bardy et al. | May 2006 | B2 |
7065407 | Bardy et al. | Jun 2006 | B2 |
7069080 | Bardy et al. | Jun 2006 | B2 |
7146212 | Bardy et al. | Dec 2006 | B2 |
7389139 | Ostroff | Jun 2008 | B2 |
20010027330 | Sullivan et al. | Oct 2001 | A1 |
20030088283 | Ostroff | May 2003 | A1 |
Number | Date | Country |
---|---|---|
0316616 | May 1989 | EP |
0347353 | Dec 1989 | EP |
0518599 | Dec 1992 | EP |
0641573 | Mar 1995 | EP |
0641573 | Jun 1997 | EP |
0518599 | Sep 1997 | EP |
0536873 | Sep 1997 | EP |
0917887 | May 1999 | EP |
0923130 | Jun 1999 | EP |
9319809 | Oct 1993 | WO |
9825349 | Jun 1998 | WO |
9903534 | Jan 1999 | WO |
9937362 | Jul 1999 | WO |
0156166 | Aug 2001 | WO |
0222208 | Mar 2002 | WO |
0224275 | Mar 2002 | WO |
0224275 | May 2002 | WO |
0222208 | Jun 2002 | WO |
02068046 | Sep 2002 | WO |
03018121 | Mar 2003 | WO |
Entry |
---|
Bardy et al., “Multicenter Experience with a Pectoral Unipolar Implantable Cardioverter-Defibrillator”, JACC, vol. 28(2), pp. 400-410, Aug. 1996. |
Friedman et al., “Implantable Defibrillators in Children: From Whence to Shock,” Journal of Cardiovascular Electrophysiology, vol. 12(3), pp. 361-362, Mar. 2001. |
Gradaus et al., “Nonthoracotomy Implantable Cardioverter Defibrillator Placement in Children: Use of Subcutaneous Array Leads and Abdominally Placed Implantable Cardiovascular Defibrillators in Children,” Journal of Cardiovascular Electrophysiology, vol. 12(3) pp. 356-360, Mar. 2001. |
Higgins et al., “The First Year Experience with the Dual Chamber ICD,” PACE, vol. 23, pp. 18-25, Jan. 2000. |
Mirowski et al., “Automatic Detection and Defibrillation of Lethal, Arrhythmias—A new Concept,” JAMA, vol. 213(4), pp. 615-616, Jul. 27, 1970. |
Olson et al., “Onset and Stability for Ventricular Tachyarrhythmia Detection in an Implantable Pacer-Cardioverter-Defibrillator,” IEEE, pp. 167-170, 1987. |
Schuder et al., “Experimental Ventricular Defibrillation with an Automatic and Completely Implanted System,” Trans. Amer. Soc. Artif. Int. Organs, vol. XVI, pp. 207-212, 1970. |
Schuder, “The role of an Engineering Oriented Medical Research Group in Developing Improved Methods and Devices for Achieving Ventricular Defibrillation: The University of Missouri Experience,” PACE, vol. 16, pp. 95-123, Jan. 1993. |
Schuder et al., “Standby Implanted Defibrillators,” Arch Intern. Med., vol. 127, p. 317 (single sheet), Feb. 1971. |
Schuder et al., “Transthoracic Ventricular Defibrillation in the Dog with Truncated and Untruncated Exponential Stimuli,” IEEE Transactions of Bio-Medical Engineering, vol. BME 18(6). |
Schwacke et al., “Komplikationen mit Sonden bei 340 Patienten mit einem Implantierbaren Kardioverter/Defibrillator,” Z Kardiol, vol. 88(8), pp. 559-565, 1999. |
Tietze et al., “Halbleiter-Schaltungstechnik,” Springer-Verlag, Berlin, Germany, pp. 784-786, 1991. |
Valenzuela et al., “Outcomes of Rapid Defibrillation by Security Offices After Cardiac Arrest in Casinos,” The New England Journal of Medicine, vol. 343(17), pp. 1206-1209, Oct. 26, 2000. |
Walters et al., “Analog to Digital Conversion Techniques in Implantable Devices,” Annual Internaational Conference of the IEEE Engineering in Medicine and Biology Society, vol. 13(4), pp. 1674-1676, 1991. |
Number | Date | Country | |
---|---|---|---|
20160166841 A1 | Jun 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12426779 | Apr 2009 | US |
Child | 15051805 | US | |
Parent | 11146607 | Jun 2005 | US |
Child | 12426779 | US | |
Parent | 10011955 | Nov 2001 | US |
Child | 11146607 | US |